Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Klotho Neurosciences ( (KLTO) ) has provided an announcement.
On July 14, 2025, Klotho Neurosciences announced that it had regained compliance with the Nasdaq listing requirements, including the minimum $1.00 bid price and the $2.5 million stockholders’ equity threshold. The company’s stock will continue to trade on the Nasdaq Capital Market under the symbols ‘KLTO’ and ‘KLTOW’ for its common stock and warrants, respectively. This compliance ensures Klotho remains listed and traded on the Nasdaq Stock Market, although Nasdaq will monitor its compliance with the stockholders’ equity requirement for a year. If Klotho falls out of compliance during this period, it may face delisting but can request a hearing.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a biogenetics company that focuses on developing innovative, disease-modifying cell and gene therapies. These therapies utilize a protein derived from a patented form of the ‘anti-aging’ human Klotho gene (s-KL) and novel delivery systems to improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays.
Average Trading Volume: 43,874,578
Technical Sentiment Signal: Buy
Current Market Cap: $67.46M
Find detailed analytics on KLTO stock on TipRanks’ Stock Analysis page.